Liraglutide: the therapeutic promise from animal models.
about
The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitusTherapy for obesity based on gastrointestinal hormonesThe use of animal models in diabetes research.Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of actionPeripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1.GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake.Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides.Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt.Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.The future of incretin-based therapy: novel avenues--novel targets.Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties.The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.Current challenges in type 2 diabetes.Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide.Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats.Effects of liraglutide in hypothalamic arcuate nucleus of obese mice.Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats.Current trends and perspectives of bioactive peptides.
P2860
Q26828940-C6720E60-0032-4730-8B5F-0762598452DCQ27006777-A7DB27B2-DFF4-43BA-A068-F44874743255Q34255921-E2439A96-6F30-4D61-BE75-FD8839E84803Q35087618-F5CB9ACA-746E-4BCC-84F3-B96D450D2FDCQ35110843-AB45DE10-69EF-4120-B52D-736863A3590DQ35543398-A1BFEC33-62A8-4161-B5FE-A45FA16D8DB5Q35744558-A39CF687-90A6-4F87-9A05-B680E78D939AQ35769584-18B02DCE-E34F-411D-BF89-56FA2DE39326Q36363950-A0103219-DA45-472F-9BFA-C3BAC987C2E0Q37142459-0588DA91-A430-4781-8087-B13D10227D2EQ37456906-7479DE51-BDF0-4C52-814B-44E7F719A19CQ37653125-2AFEB7A9-C085-40C5-B406-A9358B93357BQ37913528-203F549C-D9DB-40B8-9F82-E700FB39C29CQ37961847-B71969B8-0D34-44BE-AF10-57F4619D0EE8Q37995760-E3D5E0D9-5731-4E96-B5EE-EA0267C3A26DQ38005223-5C30F7C3-6445-420F-84B5-FFD16EEF81AAQ38071007-C6AB264B-A671-495E-B7B9-F16C8FDAFC7BQ38818082-EFD9EB02-7BAC-4E53-9779-E9FC05F0A869Q42130324-ED269CAE-40EA-4B80-B64E-60D9CF0364CEQ42557601-B6DC1AE3-0728-4121-ADF1-39CE596DBD02Q45275316-F280A004-1979-4DD9-9672-7BEAE7366FA6Q45359756-5F08EAE5-B9A6-4E12-9964-FC3C034FBF13Q48130202-74B382C3-25E6-4BFE-9F90-51F026FE8F3BQ48219629-4F403CEC-AFEB-4D10-B9D0-4A6388B0B850Q48550172-6F1B88CF-B755-4A57-BEF6-B80A4ED7681FQ48877643-AD5AFC9F-4C7C-4F29-8F3A-D7A99D5C38E7Q51311480-FDD54612-8590-43AA-9436-D6177852FA3EQ53834355-CCF22510-4976-4C7D-8973-9CC8B6A1C7A4
P2860
Liraglutide: the therapeutic promise from animal models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Liraglutide: the therapeutic promise from animal models.
@en
Liraglutide: the therapeutic promise from animal models.
@nl
type
label
Liraglutide: the therapeutic promise from animal models.
@en
Liraglutide: the therapeutic promise from animal models.
@nl
prefLabel
Liraglutide: the therapeutic promise from animal models.
@en
Liraglutide: the therapeutic promise from animal models.
@nl
P1476
Liraglutide: the therapeutic promise from animal models
@en
P2093
L B Knudsen
P356
10.1111/J.1742-1241.2010.02499.X
P577
2010-10-01T00:00:00Z